Patents by Inventor DARIA YANG

DARIA YANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10676497
    Abstract: The present disclosure provides a taxane compound and a preparation method and application thereof. The preparation method includes: protecting two hydroxyl groups in gemcitabine, conducting a condensation reaction between the protected gemcitabine and alkyl chloroformate, and removing of hydroxyl protecting groups to obtain an intermediate G1; protecting a first hydroxyl group of the intermediate G1, and then protecting the other one of the hydroxyl groups, and removing a protecting group of the first hydroxyl group to obtain an intermediate G2; reacting 7,10-di-troc-docetaxel with dianhydride to obtain an intermediate D1; conducting a condensation reaction between the intermediate D1 and the intermediate G2 to obtain an intermediate D2; and subjecting the intermediate D2 to hydroxyl deprotection to obtain a target product comprising the disclosed taxane compound.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: June 9, 2020
    Assignees: CHANGZHOU FANGYUAN PHARMACEUTICAL CO., LTD., INNER MONGOLIA PUYIN PHARMACEUTICAL CO., LTD.
    Inventors: Daria Yang, Huijuan Wang
  • Publication number: 20190256545
    Abstract: The present disclosure provides a taxane compound and a preparation method and application thereof. The preparation method includes: protecting two hydroxyl groups in gemcitabine, conducting a condensation reaction between the protected gemcitabine and alkyl chloroformate, and removing of hydroxyl protecting groups to obtain an intermediate G1; protecting a first hydroxyl group of the intermediate G1, and then protecting the other one of the hydroxyl groups, and removing a protecting group of the first hydroxyl group to obtain an intermediate G2; reacting 7,10-di-troc-docetaxel with dianhydride to obtain an intermediate D1; conducting a condensation reaction between the intermediate D1 and the intermediate G2 to obtain an intermediate D2; and subjecting the intermediate D2 to hydroxyl deprotection to obtain a target product comprising the disclosed taxane compound.
    Type: Application
    Filed: November 14, 2016
    Publication date: August 22, 2019
    Inventors: Daria YANG, Huijuan WANG
  • Patent number: 10351586
    Abstract: The present disclosure provides cytidine derivative dimers, salts and compositions of the cytidine derivative dimers, and methods of making and using the cytidine derivative dimers. The disclosed compounds are useful for treating a neoplasm in mammalian subjects. The cytidine derivative dimer has the following general formula (I). where R1 is C1-C10 alkyl, C1-C10 substituted alkyl, —(CH2)n-Ph, or substituted —(CH2)n-Ph; R2 is C1-C10alkyl, C1-C10 substituted alkyl, —(CH2)n-Ph, or substituted —(CH2)n-Ph; R3 is hydrogen, alkoxycarbonyl or substituted alkoxycarbonyl; R4 is hydrogen, alkoxycarbonyl or substituted alkoxycarbonyl; and R5 is —(CH2)n—, substituted —(CH2)n—, or —(CH2)n1—O—(CH2)n2-Ph-, where n, n1, and n2 are an integer from 0 to 3. The disclosed cytidine derivative dimers/salts provide high anti-tumor activity with low toxicity and are useful for treating cancers.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: July 16, 2019
    Assignees: CHANGZHOU FANGYUAN PHARMACEUTICAL CO., LTD, INNER MONGOLIA PUYIN PHARMACEUTICAL CO., LTD
    Inventors: Daria Yang, Haidong Wang, Hui-Juan Wang
  • Patent number: 10174067
    Abstract: The present disclosure provides a new cytidine derivative having the general formula (I), and applications thereof: As demonstrated by experiments on the growth inhibition effect of the new cytidine derivative of the present invention on HCT-116 colon cancer xenografts in tumor-bearing nude mice, the compound of the present invention has high anti-tumor activity, data of impacts on weight of nude mice bearing human colon cancer HCT-116 and data of mortality rate showed that the toxicity of the compound is comparatively low.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: January 8, 2019
    Assignees: CHANGZHOU FANGYUAN PHARMACEUTICAL CO., LTD, INNER MONGOLIA PUYIN PHARMACEUTICAL CO., LTD
    Inventors: Daria Yang, Haidong Wang, Xin Liu, Huijuan Wang
  • Publication number: 20180105550
    Abstract: The present disclosure provides cytidine derivative dimers, salts and compositions of the cytidine derivative dimers, and methods of making and using the cytidine derivative dimers that are useful for treating a neoplasm in mammalian subjects. A cytidine derivative dimer may have the following general formula (I): By molecularly designing such cytidine-based compounds, the disclosed cytidine-based derivative dimers/salts show significant inhibiting effects on HCT-116 human colon cancer cells, and exhibit strong growth inhibiting effects on HCT-116 human colon cancer xenografts grown in nude mice. The disclosed cytidine derivative dimers/salts provide high anti-tumor activity with low toxicity and are useful for treating cancers.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 19, 2018
    Inventors: DARIA YANG, HAIDONG WANG, HUI-JUAN WANG
  • Patent number: 9862741
    Abstract: The present disclosure provides cytidine derivative dimers, salts and compositions of the cytidine derivative dimers, and methods of making and using the cytidine derivative dimers. The compounds that useful for treating a neoplasm in mammalian subjects. The cytidine derivative dimer has the following general formula (I): where R1 is C1-C10 alkyl, C1-C10 substituted alkyl, —(CH2)n-Ph, or substituted —(CH2)n-Ph; R2 is C1-C10 alkyl, C1-C10 substituted alkyl, —(CH2)n-Ph, or substituted —(CH2)n-Ph; R3 is hydrogen, alkoxycarbonyl or substituted alkoxycarbonyl; R4 is hydrogen, alkoxycarbonyl or substituted alkoxycarbonyl; and R5 is —(CH2)n—, substituted —(CH2)n—, or —(CH2)n—X1—X2—, X1 being O or S, and X2 being —(CH2)n-Ph, pyrimidyl, pyranyl, imidazolyl, pyrazinyl, or pyridyl. The disclosed cytidine derivative dimers/salts provide high anti-tumor activity with low toxicity and are useful for treating cancers.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: January 9, 2018
    Assignees: CHANGZHOU PANGYUAN PHARMACEUTICAL CO., LTD, INNER MONGOLIA PUYIN PHARMACEUTICAL CO., LTD
    Inventors: Daria Yang, Haidong Wang, Hui-Juan Wang
  • Publication number: 20170355726
    Abstract: The present disclosure provides a new cytidine derivative having the general formula (I), and applications thereof: As demonstrated by experiments on the growth inhibition effect of the new cytidine derivative of the present invention on HCT-116 colon cancer xenografts in tumor-bearing nude mice, the compound of the present invention has high anti-tumor activity, data of impacts on weight of nude mice bearing human colon cancer HCT-116 and data of mortality rate showed that the toxicity of the compound is comparatively low.
    Type: Application
    Filed: June 9, 2015
    Publication date: December 14, 2017
    Inventors: Daria YANG, Haidong WANG, Xin LIU, Huijuan WANG
  • Publication number: 20160137684
    Abstract: The present disclosure provides cytidine derivative dimers, salts and compositions of the cytidine derivative dimers, and methods of making and using the cytidine derivative dimers that are useful for treating a neoplasm in mammalian subjects. A cytidine derivative dimer may have the following general formula (I): By molecularly designing such cytidine-based compounds, the disclosed cytidine-based derivative dimers/salts show significant inhibiting effects on HCT-116 human colon cancer cells, and exhibit strong growth inhibiting effects on HCT-116 human colon cancer xenografts grown in nude mice. The disclosed cytidine derivative dimers/salts provide high anti-tumor activity with low toxicity and are useful for treating cancers.
    Type: Application
    Filed: February 17, 2015
    Publication date: May 19, 2016
    Inventors: DARIA YANG, HAIDONG WANG, HUI-JUAN WANG, TERN SIONG LIEW